Prime Medicine Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
146
- Stock Symbol
-
PRME
- Share Price
-
$3.55
- (As of Friday Closing)
Prime Medicine General Information
Description
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Contact Information
Website
www.primemedicine.comCorporate Office
- 21 Erie Street
- Cambridge, MA 02139
- United States
Corporate Office
- 21 Erie Street
- Cambridge, MA 02139
- United States
Prime Medicine Stock Performance
As of 20-Nov-2026, Prime Medicine’s stock price is $3.55. Its current market cap is $792M with 223M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.55 | $3.84 | $2.67 - $5.91 | $792M | 223M | 4.63M | -$0.97 |
Prime Medicine Financials Summary
As of 30-Sep-2026, Prime Medicine has a trailing 12-month revenue of $7.06M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 554,106 | 531,220 | 248,711 | 714,017 |
| Revenue | 7,061 | 4,632 | 2,983 | 0 |
| EBITDA | (172,524) | (197,970) | (193,276) | (196,570) |
| Net Income | (176,353) | (201,142) | (195,882) | (198,133) |
| Total Assets | 213,855 | 342,733 | 297,508 | 193,851 |
| Total Debt | 110,421 | 116,427 | 40,794 | 13,633 |
Prime Medicine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Prime Medicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Prime Medicine Comparisons
Industry
Financing
Details
Prime Medicine Competitors (4)
One of Prime Medicine’s 4 competitors is Beam Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Beam Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA |
Prime Medicine Patents
Prime Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026198578-A1 | Genome editing compositions and methods for treatment of alpha-1-antitrypsin deficiency | Pending | 17-Mar-2025 | ||
| WO-2026090412-A1 | Building blocks for gainac-based lipids | Pending | 23-Oct-2024 | ||
| WO-2026090423-A1 | Universal lnp compositions | Pending | 23-Oct-2024 | ||
| WO-2025111430-A1 | Chemical modifications in mrna poly(a) tail | Inactive | 21-Nov-2023 | ||
| WO-2025111452-A2 | Chemical modifications in pegrna and ngrnas | Inactive | 21-Nov-2023 | C12N15/113 |
Prime Medicine Signals
Prime Medicine ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.85 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Prime Medicine FAQs
-
When was Prime Medicine founded?
Prime Medicine was founded in 2019.
-
Where is Prime Medicine headquartered?
Prime Medicine is headquartered in Cambridge, MA.
-
What is the size of Prime Medicine?
Prime Medicine has 146 total employees.
-
What industry is Prime Medicine in?
Prime Medicine’s primary industry is Drug Discovery.
-
Is Prime Medicine a private or public company?
Prime Medicine is a Public company.
-
What is Prime Medicine’s stock symbol?
The ticker symbol for Prime Medicine is PRME.
-
What is the current stock price of Prime Medicine?
As of 20-Nov-2026 the stock price of Prime Medicine is $3.55.
-
What is the current market cap of Prime Medicine?
The current market capitalization of Prime Medicine is $792M.
-
What is Prime Medicine’s current revenue?
The trailing twelve month revenue for Prime Medicine is $7.06M.
-
Who are Prime Medicine’s competitors?
Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine are competitors of Prime Medicine.
-
What is Prime Medicine’s annual earnings per share (EPS)?
Prime Medicine’s EPS for 12 months was -$0.97.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process